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Introduction
As identified in previously published articles, including those published in this issue, the 
detection of early cognitive impairment among older adult populations is worthy of 
diagnostic and clinical recognition. Several definitions and classifications have been applied 
to this form of cognitive impairment over time1–4 including mild cognitive impairment 
(MCI),4–6 cognitive impairment no dementia,7,8 malignant senescent forgetfulness,9 and 
age-associated cognitive decline.10 Consistent with current usage this review uses the term 
MCI, and focuses on progression from MCI to dementia.
Prevalence estimates of MCI among populations of community-dwelling older adults are as 
high as 22% of those aged 71 years and older,11 with prevalence rates among older adults 
cared for in memory care practices estimated at nearly 40%.12 The likelihood of progression 
from MCI to any form of dementia has been suggested to occur at a rate 3 to 5 times higher 
than those with normal cognition,4,13–15 with an annual rate of progression of 12% in the 
general population and up to 20% in populations at higher risk.11 As a transitional stage of 
early cognitive impairment, much attention has been focused on the identification of 
modifiable and nonmodifiable risk factors to prevent or delay the progression of MCI to 
dementia.
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Several known risk factors for the development of dementias have been identified, including 
age, genetic characteristics, lower educational attainment, and various clinical 
characteristics.16–20 Among those with MCI, several risk factors influencing the progression 
to dementia have been identified and are discussed in detail in this clinical review. Early 
studies aiming to prevent the onset of Alzheimer-type dementia among older adults with 
amnestic MCI have been reported, including a study using the only approved pharmacologic 
class in dementia, acetylcholinesterase inhibitors, or vitamin E. The investigators reported 
that acetylcholinesterase inhibitors did not delay the progression to Alzheimer-type dementia 
over 3 years, except in those who were carriers of an apolipoprotein ε4 (APOE ε4) allele.21 
A second study evaluating donepezil in reducing the progression of MCI did not show 
significant improvement in cognition with higher adverse events and dropouts, but did not 
evaluate for the presence of APOE alleles or the diagnosis of dementia as an outcome.22 A 
second prevention study found that cognitive training did not delay the progression from 
MCI to dementia.23 Additional studies evaluating potential methods to delay or reduce the 
likelihood of progression from MCI to dementia have generally found no evidence of 
support for nonsteroidal anti-inflammatory drugs (NSAIDs) or ginkgo biloba,24–26 further 
limiting the potential therapeutic options.
To assist clinicians in understanding factors associated with the progression from MCI to 
dementia, this article reviews both markers of disease activity and clinical risk factors 
influencing the progression of MCI to dementia. Biomarkers and imaging characteristics 
have been extensively studied as pathologic indicators of neurologic disease. The authors 
first review the validity of biomarkers in monitoring the progression from MCI to dementia. 
Risk factors for the progression of MCI to dementia are then reviewed, and categorized as 
modifiable and nonmodifiable. Modifiable risk factors, such as cardiovascular risk factors, 
depression, or adverse drug effects, are defined as characteristics that, if manipulated (such 
as improved success at treatment goals), may modify the risk or rate of progression to 
dementia. Nonmodifiable risk factors are defined as risk factors that cannot be manipulated, 
such as demographic or genetic characteristics. Such categorization may provide a platform 
for future clinical interventions targeting modifiable risk factors to reduce the progression of 
MCI to dementia.
Markers of Disease Process
Imaging
Progressive atrophy of the brain can be detected by structural magnetic resonance imaging 
(MRI), and has been shown to monitor the disease process in those developing Alzheimer-
type dementia.27–30 Structural MRI has proven sensitivity in monitoring changes with aging,
31–33
 and is also sensitive to the detection of a more rapid rate of change as seen when 
cognitive symptoms progress to dementia.34 The patterns of change within various regions 
of the cortex have been shown to have predictive value for progressive cognitive impairment 
and Alzheimer-type dementia among those with MCI.35–37 A small study of Italian older 
adults with MCI found that atrophy of the medial temporal lobe identified on MRI was a 
better predictor of the progression from MCI to any form of dementia than were baseline 
neuropsychiatric assessments and demographic characteristics.38
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White matter lesions (WML) are recognized as areas of higher signal intensity on MRI and 
are common in older adults, with higher frequencies among those with vascular risk factors.
39–41
 Compared with healthy controls, these lesions are progressively more extensive among 
those with MCI and both vascular and Alzheimer-type dementia.42,43 A higher severity of 
lesions has also been identified in those with worse cognitive impairment reported by 
neuropsychiatric assessment in comparison with healthy controls.41,44 A recent study by 
Devine and colleagues45 evaluated the WML severity and the time to conversion to any form 
of dementia among a small group of older adults with MCI receiving care in a memory 
clinic in the United Kingdom. The investigators found no relationship between WML 
severity and the time to progression to dementia. Age and subtype of dementia were the only 
independent variables associated with a shorter time to conversion to dementia, noting that 
more advanced age and the amnestic subtype of MCI progressed to dementia sooner. As 
Alzheimer-type dementia was the primary type of dementia diagnosed in this group (62%), 
this result appears to be consistent with a recent review by Debette and Markus46 suggesting 
that WML reflect cardiovascular disease burden and are more consistently associated with 
an increased risk of the progression to vascular or mixed dementias, but not Alzheimer-type 
dementia. However, a recent article by Brickman and colleagues47 shows an association 
between white matter hyperintensities and incident Alzheimer-type dementia in a population 
without MCI at baseline. The conflicting evidence underscores a lack of accepted opinion in 
this matter. In addition, a study by Bombois and colleagues48 also supports the association 
of imaging with vascular and mixed dementia, noting that increasing amounts of subcortical 
hyperintensities were only associated with vascular or mixed dementias.
Central and Peripheral Biomarkers
Cerebrospinal fluid (CSF) biomarkers, focusing on detection of Tau proteins and amyloid-β 
(Aβ) proteins, have also been studied as predictors of the progression of MCI to Alzheimer-
type dementia.49–52 Because of their predictive value, structural MRI and CSF biomarkers 
have been used as outcome measures to increase trial power and reduce the sample-size 
burden.53,54 In addition, biomarkers have been incorporated into recently released 
recommendations from the National Institute on Aging and the Alzheimer's Association for 
the recognition of MCI and stratification into diagnostic subtypes of MCI that better 
describe the risk of progression to Alzheimer-type dementias.55
Time to progression of MCI has been evaluated by CSF biomarkers and MRI results in 91 
Dutch older adults with MCI who progressed to Alzheimer-type dementia.56 Predictors of 
time to progression of MCI to Alzheimer-type dementia included only atrophy of medial 
temporal lobe (hazard ratio [HR] 2.6, 95% confidence interval [CI] 1.1–6.1; P = .03), 
whereas APOE ε4 genotype and Aβ1–42 were not associated with time to progression to 
Alzheimer-type dementia. This result suggests that markers of brain injury (such as Tau 
proteins or imaging results suggesting progressive neurologic damage), but not pathologic 
markers (such as Aβ1–42), may better predict the time to progression to Alzheimer-type 
dementia among older adults with MCI.56
Peripheral biomarkers have also been considered, given the challenges in acquiring CSF 
samples and translating CSF studies to the general population. To date the evaluation of 
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peripheral markers, including various species of cytokines,57–59 Aβ and other serum 
proteins, 60–68 and APOE ε isoforms,69 have not identified clear and reproducible peripheral 
biomarkers associated with an increased risk of Alzheimer-type dementia. Llano and 
colleagues70 recently published on the use of data from the Alzheimer's Disease 
Neuroimaging (ADNI) project to identify 5 plasma analytes with modest predictive value in 
differentiating subjects with Alzheimer-type dementia from normal controls (range of 
sensitivity and specificity 74%–85%). No signature panel was able to adequately predict the 
progression from MCI to Alzheimer-type dementia within this ADNI population. The 
investigators recognize that the signature panels have insufficient predictive value 
independently, but theorize that these groups of markers may have value in the future as part 
of a multicomponent predictive tool.
A recent study by Choo and colleagues71 pursued the hypothesis that combinations of 
biomarkers and imaging results would improve the prediction of progression to Alzheimer-
type dementia among Swedish older adults with a diagnosis of MCI. After performing a 
stepwise multivariate logistic regression analysis for the outcome of Alzheimer-type 
dementia only, the investigators reported parietal glucose metabolic rate and total Tau 
proteins predicted the progression from MCI to Alzheimer-type dementia. Although APOE 
genotype, a known predictor for dementia, did predict progression in univariate models, it 
did not add further predictive capability to the 2-predictor model in this cohort.
Nonmodifiable Risk Factors
Genetic Characteristics
Long recognized as a risk factor for Alzheimer-type dementia and even MCI, the APOE ε4 
allele has emerged as the most consistent genetic risk factor for the progression of MCI to 
Alzheimer-type dementia.72 A meta-analysis published in 2011 included data from 35 
studies with more than 6000 subjects to evaluate this and other genetic risk factors.73 The 
meta-analysis reports that among those with MCI, carriers of any APOE ε4 allele are more 
than 2 times as likely to progress to Alzheimer-type dementia (Table 1). Homozygotes for 
the APOE ε4 allele had a 4-fold higher risk of progressing to Alzheimer-type dementia 
compared with noncarriers. Of note, this review did not include results from the Nun study, 
which did not find an association between APOE status and the outcome of any dementia.74 
Although the risk of Alzheimer-type dementia was found to be higher, the clinical utility of 
exclusively using APOE genotype to predict progression to dementia was attenuated by a 
low sensitivity and specificity (0.53 and 0.67, respectively).73
Rodriguez-Rodriguez and colleagues75 studied the link between 8 genetic variants with the 
risk of progression to Alzheimer-type dementia or with the speed of progression to 
Alzheimer-type dementia. Among 297 patients seen in a Spanish neurology clinic with a 
diagnosis of MCI, only 2 genetic variants had an impact on the progression to Alzheimer-
type dementia. As expected, the APOE ε4 allele more than quadrupled the risk of 
progression to Alzheimer-type dementia (P<.001). Carriers of the clusterin (CLU) T-allele 
had a lower risk of conversion to Alzheimer-type dementia than noncarriers of the T-allele. 
With respect to speed of progression, APOE was the only individual genetic predictor of a 
more rapid progression (HR 1.77, 95% CI 1.05–2.97; P = .030). In addition, the investigators 
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reported that carriers of at least 6 non-APOE genetic variants had a 2-fold increased risk of 
more rapid progression to Alzheimer-type dementia.
Subtype of MCI
The National Institute on Aging and Alzheimer's Association recently released 
recommendations for the stratification of MCI categories in the context of the likelihood of 
progression to Alzheimer-type dementia.55 Categorization into such groups is based on 
neuroimaging (such as atrophy of medial temporal lobe) and biomarkers (such as Tau 
proteins and Aβ1–42). Four categories are proposed: those with high likelihood to progress to 
Alzheimer-type dementia, intermediate likelihood, unlikely, and a core group with 
conflicting results (Table 2). Two studies validated these categories using different 
populations enrolled either in the ADNI study76 or the Alzheimer's Disease Research Center 
or Mayo Clinic Study on Aging cohorts.77 Guo and colleagues76 found a higher risk of 
progression to Alzheimer-type dementia when the high-risk group was compared with the 
core group (HR 2.3, 95% CI 1.4–3.9; P = .002). Jack and colleagues77 used the criteria to 
classify preclinical disease (among those with normal cognition), to improve the 
understanding of the disease process and promote the optimal intervention point to minimize 
future disease progression. However, because categorical definitions for early disease 
processes and MCI subtypes has been recently released, the majority of categorization 
schemes have defined MCI subtypes as amnestic or nonamnestic and single-domain or 
multi-domain characteristics.
A subtype of MCI was suggested to identify the possible neurologic abnormality to describe 
the progression to different dementias in a study of older adults with MCI cared for in a 
California Alzheimer disease center.13 After a mean follow-up time of 3 years, 65% 
progressed to any form of dementia; those with amnestic forms of MCI were more likely to 
progress to Alzheimer-type dementia, whereas nonamnestic forms were more likely to 
progress to vascular or frontotemporal dementia. Similarly, in a population of 60 Italian 
older adults followed for a mean of 4 years, any type of MCI increased the risk for any 
dementia (HR 3.02, 95% CI 1.86–4.89) as well as Alzheimer-type dementia (HR 3.21, 95% 
CI 1.77–5.81), but not vascular dementia. This risk appeared to be attributable to the risk of 
amnestic MCI in the progression to any dementia (see Table 1); and, interestingly, the risk of 
progression to any dementia was no different among those with nonamnestic MCI and those 
without MCI. However, it must be noted that the sample size with nonamnestic MCI was too 
small to draw conclusions.78
Zhou and colleagues79 recently highlighted predictors of progression to dementia among the 
ADNI cohort with MCI by focusing on demographic, genetic, imaging, and cognitive 
assessments conducted at baseline. The investigators conducted Cox proportional hazard 
regression models to identify variables increasing the risk of progression to dementia, and 
further characterized these risks into survival trees. Stepwise Cox regression analysis 
determined the Alzheimer's Disease Assessment Scale with 13 items (ADAS13) and logical 
memory with delayed recall as the 2 tests most frequently identifying abnormal results. 
Alzheimer-type dementia developed in the entire cohort at a rate of 5.6% at 12 months and 
58.1% at 48 months. Considering a combination of baseline ADAS13 scores greater than 
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15.67 and Clinical Dementia Rating scale sum of boxes (CDR-sob) scores greater than 1.5 
yielded an incident Alzheimer-type dementia rate of 12.9% at 12 months and 92.7% at 48 
months. Using the ADAS13 as the first categorization method, the strength of this predictive 
risk stratification was similar when either baseline battery tests or imaging measures of 
cortical thickness of the right inferior temporal lobe were used, all with a similar c-index of 
0.68. Although a promising lead, it must be restated that the population included in the 
ADNI cohort may have limited translation to populations cared for in many clinical settings.
In an alternative and complementary approach, Koepsell and Monsell80 pursued this 
research question with the objective of identifying predictors of the reversion from MCI to 
normal cognitive function. The investigators used a cohort of approximately 3000 subjects 
from the National Alzheimer's Coordinating Center who were at least 65 years old and 
diagnosed with MCI. After a follow-up period of approximately 1 year, 5 risk factors 
predicting reversion from MCI to normal cognition were identified: higher baseline Mini-
Mental State Examination (MMSE) scores, lower CDR-sob scores, fewer functional 
impairments, nonamnestic single-domain subtype of MCI, and a lack of APOE ε4 genotype. 
Of note, these results did not incorporate clinical factors such as burden of vascular disease, 
and categorized normal cognition as either normal or “impaired but not MCI” as the 
outcome measure, stating that categorization across multiple centers used each term with 
variable frequencies. However, the investigators also identified a trend among those patients 
with MCI who reverted to normal cognitive function that suggests they were more likely to 
transition back to MCI or to dementia than those cognitively normal at baseline.80
Modifiable Risk Factors
Comorbidity and Other Clinical Characteristics
Chronic comorbid disease such as coronary heart disease and hypertension are common in 
older adults who develop cognitive impairment,81,82 often requiring the use of several 
medications to reach therapeutic goals. It has been documented that ambulatory older adults 
use an average of 11 medications per day and that 74% combine prescription medications 
and dietary supplements.83,84 Incident cognitive impairment has been suggested to be less 
likely in those using medications to control for vascular risk factors85–89; however, other 
medications may result in adverse cognitive outcomes, such as MCI, and represent a 
potentially reversible risk factor.
A descriptive analysis of a population with cognitive impairment (either MCI or dementia) 
from the Cache County study suggests that those with cognitive impairment have a more 
severe burden of comorbid disease than those without cognitive impairment.90 Vascular 
disease has been considered the most likely comorbidity to cause a more rapid progression 
of cognitive impairment. One study involving approximately 500 older adults from a 
Midwestern Alzheimer disease center evaluated risk factors for progression from MCI to 
dementia. Using a Markov chain model to assess the transition from one cognitive state to 
another, the investigators did not find an influence of demographic, genetic, or education on 
the progression to dementia, but rather found that a baseline history of hypertension reduced 
the likelihood of progression to dementia. This population was largely Caucasian and 
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educated, possibly indicating a higher likelihood of adherence to medications to control 
hypertension and reduce the burden of vascular disease.
Investigators from the Italian Longitudinal Study in Aging focused an analysis of their 
population-based database on the relationship of metabolic syndrome with the progression 
of MCI to dementia.91 Metabolic syndrome is recognized by the presence of at least 3 of the 
following features: abdominal obesity (measured by waist circumference), elevated plasma 
triglyceride levels of at least 150 mg/dL, low high-density lipoprotein cholesterol (<40 
mg/dL for men and <50 mg/dL for women), high blood pressure (≥130/≥85 mm Hg), or use 
of antihypertensive treatment. The study observed approximately 2100 patients over a mean 
of 3.5 years, only 121 of whom had MCI. Multivariate models adjusting for several potential 
demographic and cardiovascular confounders revealed a higher risk of progression to any 
dementia among those with metabolic syndrome. Within this same population, interestingly 
no relationship between metabolic syndrome and incident MCI was identified.
A prospective study of 257 Chinese older adults with MCI was conducted to identify risk 
factors for the progression of cognitive decline (evaluated by MMSE score), progression 
from MCI to any dementia, and progression from MCI to Alzheimer-type dementia.92 The 
investigators considered vascular risk factors of diabetes, hypertension, hyperlipidemia, and 
tobacco and alcohol use over a 3-year observation period. MRI and computed tomographic 
angiography (CTA) were used to identify changes in white matter and degree of cerebral 
arteriostenosis. Considering all clinical variables and imaging results, diabetes, baseline 
severity of white matter change, and carotid stenosis were robust predictors for each 
outcome, including any dementia and Alzheimer-type dementia. The investigators evaluated 
the impact of antihypertensive use and oral hypoglycemic or insulin use, and found no 
association with the progression to dementia.92 Such results suggest that vascular risk 
factors resulting in chronic cerebral hypoperfusion have a negative impact on cognitive 
function and may advance the progression to any form of dementia.
A similar study conducted in an Italian population of community-dwelling older adults with 
a diagnosis of MCI followed 245 subjects over approximately 2.5 years to evaluate the 
impact of vascular diseases on the progression of MCI to dementia.93 Vascular diseases were 
recognized by the Hachinski Ischemic Score and the Framing-ham Stroke Risk Profile. The 
Hachinksi score is a marker of existing cerebrovascular disease, whereas the Framingham 
Stroke Risk Profile is a marker of future cerebrovascular disease risk. The investigators also 
considered the presence of APOE ε4, smoking status, and the presence of WML as 
covariates in the analysis. The results suggest that among the 52% of subjects who 
progressed to dementia during the observation period, no individual clinical factor or 
vascular summary score was associated with an increased risk of progression to dementia. 
However, the combination of Hachinski scores greater than 4 with presence of WML near 
the basal ganglia increased the risk of progression to any form of dementia as well as to 
Alzheimer-type dementia (HR 3.8, 95% CI 1.2–11.5) after adjusting for age, sex, education, 
cumulative illness, MMSE, MCI subtype, and APOE genotype. Framingham Stroke Risk 
Profile was not associated with an increased risk of progression to dementia, either alone or 
in combination with imaging results.
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Other notable studies have evaluated the role of vascular risk factors on the development of 
dementia, with conflicting results. Results from some observational studies have produced 
similar results that show no association between individual risk of cardiovascular disease 
and incident dementia,13,94–96 whereas others have suggested vascular risk factors may 
independently increase the risk of progression to dementia.97–99 In 2004 DeCarli and 
colleagues95 reported from a cohort of older adults with MCI and calculated vascular risk 
through a composite score as the sum of vascular risk factors (up to 6). The investigators 
also defined Alzheimer-type dementia as a progression from a CDR-sob score of 0.5 to 1.0 
or greater. Although limitations in the population as well as the methods are noted, no 
association between baseline vascular risk factors and progression to Alzheimer-type 
dementia was identified.
A Swedish longitudinal study on aging reported on the impact of diabetes and pre-diabetes 
on the progression from MCI to dementia. Approximately 300 subjects with MCI at baseline 
were followed for a mean of 3 years. After controlling for age, sex, education, body mass 
index, genotype, and vascular disorders, the risk of progression to any dementia (see Table 
1) and Alzheimer-type dementia was increased by a diagnosis of diabetes and prediabetes 
(HR 4.22, 95% CI1.57–9.01). Kaplan-Meier survival analysis suggested that diabetes 
accelerated the time to progression to dementia by an average of 3.2 years. Of note, no risk 
of incident MCI was identified in older adults with diabetes and normal cognition at 
baseline.98
A recent observational study conducted in a Chinese population over 5 years suggests that 
vascular risk factors increase the progression of MCI to Alzheimer-type dementia.99 The 
investigators report that vascular risk factors (including hypertension, diabetes, 
cerebrovascular disease, and hypercholesterolemia) additively increase the risk of 
progression to Alzheimer-type dementia, and that treatment of vascular disease was 
associated with a reduction in the risk of conversion to dementia. Although medication 
adherence and clinical treatment targets were not assessed, this study gives strong support to 
interventions aimed at managing vascular risk factors in those with MCI as a method to 
reduce the progression to dementia. Further support for the treatment of vascular disease in 
reducing the neuropathology of Alzheimer-type dementia was published in 2009 by 
Hoffman and colleagues, who used autopsy evidence to show fewer neuritic plaques and 
neurofibrillary tangles in those with hypertension who received antihypertensive medication 
than in those not receiving antihypertensive medication.22
Contrasting such results, a secondary analysis of the Ginkgo Evaluation in Memory Study 
described the role of statins on the progression from MCI to dementia in this observational 
study.100 Among those with a baseline diagnosis of MCI, statins were found to have no 
influence on the progression from MCI to all-cause or Alzheimer-type dementia, although 
statins were shown to reduce incident dementia in the cohort that was cognitively normal at 
baseline (HR 0.79, 95% CI 0.65–0.96). Though a promising result for incident dementia, 
this analysis was conducted with self-reported measures of medication exposure, suggesting 
this association requires further study with more accurate measures of medication exposure 
as well as control of disease state.
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Neuropsychiatric Symptoms
Neuropsychiatric symptoms have been reported in up to 30% of older adults with a 
diagnosis of MCI.101 Because neuropsychiatric symptoms have been associated with a 
worse prognosis in dementia,102 the relationship between neuropsychiatric symptoms and 
the risk for progression of MCI to dementia was assessed in a population enrolled from 
Cache County, Utah.103 A cohort of 230 older adults diagnosed with MCI was evaluated for 
predictors of progression to any dementia using a cognitive and neuropsychiatric battery 
(MMSE, Modified MMSE, CDR, and the Neuropsychiatric Inventory [NPI]). In multivariate 
regression models controlling for age, education, and APOE status, nighttime behaviors 
predicted progression to all-cause dementia (HR 1.28, 95% CI 1.08–1.52) and hallucinations 
predicted progression only to vascular dementia, not all-cause or Alzheimer-type dementia 
(HR 10.1, 95% CI1.1–91.1). Overall scores on the NPI suggest that even a minor severity of 
neuropsychiatric symptoms increases the risk of progression to any dementia (HR 1.65, 95% 
CI 1.01–2.69). Despite the relatively small sample size, this study suggests that further 
attention to and possibly specific interventions targeting those with neuropsychiatric 
symptoms may reduce the progression of MCI to dementia.
Other psychiatric symptoms have been evaluated as potential risk factors for the progression 
of MCI to dementia. Prior work has identified depression and anxiety as 2 risk factors 
increasing such progression.104–106 Two of these studies present conflicting results on the 
role of depression in the progression of MCI. Whereas both studies assessed depression and 
anxiety with an outcome of Alzheimer-type dementia in populations with amnestic or 
multidomain MCI, Palmer and colleagues106 suggest that depression alone does not increase 
the risk of progression to dementia except in those with normal cognition, whereas Modrego 
and Ferrandez105 report that the risk of progression is nearly 2-fold in those with depressive 
symptoms. The 2 studies used different tools to identify depression symptoms, with 
Modrego using the Geriatric Depression Scale and Palmer identifying symptoms through the 
Comprehensive Psychopathological Rating Scale.105,106 Controversially, the recent study by 
Peters and colleagues103 described earlier does not suggest that either depression or anxiety, 
assessed as domains in the NPI, influenced the progression of MCI to dementia. It must be 
borne in mind that depression and anxiety assessments in the NPI are single-item responses, 
in comparison with other screening tools assessing 15 to 30 items. However, when Peters 
and colleagues103 grouped mood-related domains of depression, anxiety, apathy, and 
irritability together, no impact on disease progression was revealed. Of note, a recent study 
by Richard and colleagues104 found that apathy, but not depressive symptoms, increased the 
risk of progression from MCI to Alzheimer-type dementia.
The combination of consistent antidepressant treatment (flexible regimen) with or without 
donepezil in older adults with major depression was recently evaluated. In the cohort with 
MCI at baseline, adding donepezil to the antidepressant regimen reduced the likelihood of 
progression to dementia over the 2-year study period; however, this group was also more 
likely to experience a recurrence of major depression (44% vs 12%, likelihood ratio 4.91; P 
= .03).107 The investigators appropriately concluded that the potential benefits of adjuvant 
donepezil and antidepressant therapy require further study, and strong consideration of the 
risks in the face of the potential benefits.
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Future Considerations
Risk stratification based on factors identified in observational studies may offer an 
opportunity to focus interventions on reducing the risk of incident dementia in those patients 
at highest risk. As described earlier,79 existing databases of cohorts with MCI have been 
used to predict the transition to dementia. Fig. 1 summarizes the risk factors previously 
identified to modify the progression from MCI to normal cognition, mixed or vascular 
dementia, or Alzheimer-type dementia. As a starting point, these results represent promising 
methods of identifying those populations at highest risk; however, the limitations of such 
cohorts from the existing literature, often composed of participants involved in research 
activity, may not represent the population encountered in many clinical environments and 
reduces the clinical applicability of such results. Similarly, no study has yet focused on 
interventions such as control of cardiovascular risk factors specifically in those with MCI, 
making risk-stratification methods applicable to only research environments. To date, studies 
evaluating the use of acetylcholinesterase inhibitors, NSAIDs, and ginkgo biloba have not 
yielded results promoting their routine use in clinical practice among those with MCI.
Further evidence is necessary to clarify the impact of comorbid disease, specifically related 
to the level of disease control, on the progression of MCI to dementia. As noted earlier, there 
has recently been a significant amount of activity toward understanding the role of comorbid 
disease on the progression of cognitive impairment. Findings that the treatment of comorbid 
vascular disease may reduce the likelihood of progression to dementia are promising22,99; 
however, no consideration of the intensity of treatment such as target blood pressure or 
hemoglobin A1c has been considered. Considering the complexity of medication 
management and adherence in this population, especially among those experiencing 
difficulty in executive function, this issue of disease-state control should be pursued with 
careful attention to risks and benefits of medications. Appropriate methods for assessing 
medication adherence and monitoring plans that frequently address potential adverse events 
should be established by clinicians in attempting to control multiple comorbidities in this 
frail older adult population.
Lastly, although associations between modifiable risk factors, such as hypertension and 
diabetes, have been suggested, little evidence in the identification of potentially relevant, 
nonvascular disease states has been pursued, such as oxygen deprivation states of asthma/
chronic obstructive pulmonary disease, and severe heart failure. Similarly, certain 
medications thought to temporarily or permanently impair cognitive function, including 
anticholinergics, benzodiazepines, and possibly statins, are poorly represented in the existing 
literature.
Summary
Several risk factors for the progression of cognitive impairment in those diagnosed with 
MCI have been considered. The variability in results found in the existing literature arises in 
part from the heterogeneity in populations studied, subtypes of MCI considered, and 
dementia outcomes evaluated as study end points. Risk factors identified to increase the risk 
of Alzheimer disease pathology include the presence of deep WML combined with 
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Hachinski Ischemic Scores greater than 4, the presence of APOE ε4 and absence of CLU 
genotypes, presence of more than 6 genetic markers for Alzheimer-type dementia, amnestic 
subtype of MCI, psychiatric symptoms of anxiety, depression, or apathy, and presence of 
diabetes or prediabetes. Risk factors increasing the risk of mixed or vascular dementias 
include carotid stenosis, diabetes (or prediabetes), depression, low blood pressure, and atrial 
fibrillation.
From a researcher's perspective, this information is of value as it may improve population 
selection, design of the intervention, and definition of the outcomes of interest in the quest to 
minimize the progression of MCI to dementia. Clinicians, patients, and the health care 
system value this information because it permits a more informed conversation about disease 
prevention, clinical treatment, and advanced care planning. The risk factors identified thus 
far represent modifiable and nonmodifiable variables to be incorporated into both research 
and clinical practice as possible targets for prevention and treatment of progressive cognitive 
impairment. Given the recognition of common comorbid conditions such as hypertension 
and diabetes as potentially modifiable risk factors, future management of prevention 
strategies for the progression of MCI to dementia is likely to fall into the hands of primary 
care and general practice physicians and mid-level providers.
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Key Points
• Medial temporal lobe atrophy, total Tau proteins, and Aβ1–42 have been used 
as markers of disease processes that improve the identification of preclinical 
cognitive impairment.
• Modifiable risk factors, such as hypertension, diabetes, and depression, 
represent potential areas for therapeutic interventions to minimize the 
progression of mild cognitive impairment (MCI).
• Future interventions targeting cardiovascular and other clinical interventions 
must consider the complexities of medication management in attempts to 
reduce the progression of MCI to dementia.
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Fig. 1. 
Risk factors for progression of MCI to normal cognition, vascular or mixed dementia, or 
Alzheimer-type dementia. APOE, apolipoprotein; CDR-sob, Clinical Dementia Rating scale 
sum of boxes; CLU, clusterin; HIS, Hachinski Ischemic Score; MMSE, Mini-Mental Status 
Examination; MCI, mild cognitive impairment; MTL, medial temporal lobe; t-Tau, total Tau 
protein from cerebrospinal fluid; WML, white matter lesions.
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Table 2
Risk stratification of MCI subtypes as defined by the NIA-AA
Core Criteria: Apply to All MCI Subtype
Biomarker Indicator
Neuronal Injury Result Imaging Result
1. Complaint of change in cognitive function MCI Unlikely Negative Negative
MCI Core Untested/indeterminate Untested/indeterminate
2. Impairment in more than 1 cognitive domain MCI Intermediate Untested/indeterminate Positive
Positive Untested/indeterminate
3. No decline in function MCI High Positive Positive
4. Not dementia
Abbreviations: MCI, mild cognitive impairment; NIA-AA, National Institute on Aging–Alzheimer's Association.
Adapted from Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: 
recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. 
Alzheimers Dement 2011;7(3):270–9.
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